AAPG Stock: Price, Forecast, Financials & AI Analysis

High

28.320

Open

28.010

VWAP

28.30

Vol

1.99K

Mkt Cap

Low

28.000

Amount

56.38K

EV/EBITDA(TTM)

Total Shares

2.62B

EV/OCF(TTM)

P/S(TTM)

41.90

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

Events Timeline

(ET)

2026-01-06

20:10:00

Ascentage Pharma's APG-3288 Receives FDA Clearance for Clinical Study

2025-12-07 (ET)

2025-12-07

21:00:00

Ascentage Pharma Presents Latest Study Results of Lisaftoclax at ASH Meeting

2025-12-07

13:20:00

Ascentage Pharma Presents Latest Phase II Study Results of Lisaftoclax at ASH Meeting

News

8.5

01:47 AMGlobenewswire

PinnedAscentage Pharma's Dual-Engine Growth: Global Innovation Strategy for 2026

2.0

01-07Benzinga

Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release

9.0

01-07Globenewswire

Ascentage Pharma's APG-3288 Receives FDA IND Clearance for Clinical Study

5.0

2025-12-23Benzinga

Novo Nordisk Receives FDA Approval for Wegovy, Shares Surge 8.6%

2.0

2025-12-16Benzinga

Cementos Pacasmayo, Rezolve AI, Emerald Holding, and Other Major Stocks Rising on Monday

9.0

2025-12-09Newsfilter

Ascentage Pharma Reports Four-Year Efficacy Data for Olverembatinib

4 Analyst Rating

Wall Street analysts forecast AAPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG is 48.50 USD with a low forecast of 45.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

45.00

Averages

48.50

High

51.00

Current: 0.000

Low

45.00

Averages

48.50

High

51.00

Lucid Capital

NULL

Buy

initiated

$50

Al Analysis

2025-12-15

Reason

Lucid Capital

Price Target

$50

Al Analysis

2025-12-15

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Ascentage Pharma with a Buy rating and $50 price target. The firm says Ascentage is a commercial-stage biotechnology company focused on developing next generation tyrosine kinase inhibitors for oncology. The company has the potential to develop and commercialize "differentiated" assets with validated targets in multi-blockbuster opportunities, offering significant upside for somewhat mitigated risk, the analyst tells investors in a research note.

Oppenheimer

Matthew Biegler

Outperform

initiated

$45

2025-12-04

Reason

Oppenheimer

Matthew Biegler

Price Target

$45

2025-12-04

initiated

Outperform

Reason

Oppenheimer analyst Matthew Biegler initiated coverage of Ascentage Pharma with an Outperform rating and $45 price target. The firm believes Ascentage has the potential to become the next BeOne. To get there, they're taking a page from BeOne's playbook. Better drugs, focusing on chronic blood cancers with large TAMs, Oppenheimer argues, adding that olverembatinib looks like a best-in-class BCR-ABL inhibitor. Separately, Ascentage's BCL-2 inhibitor lisaftoclax is taking aim at BeOne's biggest market: Chronic Lymphocytic Leukemia. The firm believes lisaftoclax' tolerability could enable it to make inroads into an indication where other BCL-2 inhibitors have failed, namely Myelodysplastic syndrome.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AAPG

Unlock Now

Valuation Metrics

The current forward P/E ratio for Ascentage Pharma Group International (AAPG.O) is -28.16, compared to its 5-year average forward P/E of -27.84. For a more detailed relative valuation and DCF analysis to assess Ascentage Pharma Group International 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.84

Current PE

-28.16

Overvalued PE

2.10

Undervalued PE

-57.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-159.77

Current EV/EBITDA

-311.97

Overvalued EV/EBITDA

40.07

Undervalued EV/EBITDA

-359.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

23.32

Current PS

14.11

Overvalued PS

32.02

Undervalued PS

14.61

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Ascentage Pharma Group International (AAPG) stock price today?

The current price of AAPG is 28.32 USD — it has increased 1.98 % in the last trading day.

What is Ascentage Pharma Group International (AAPG)'s business?

What is the price predicton of AAPG Stock?

Wall Street analysts forecast AAPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG is48.50 USD with a low forecast of 45.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Ascentage Pharma Group International (AAPG)'s revenue for the last quarter?

Ascentage Pharma Group International revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Ascentage Pharma Group International (AAPG)'s earnings per share (EPS) for the last quarter?

Ascentage Pharma Group International. EPS for the last quarter amounts to USD, decreased % YoY.

How many employees does Ascentage Pharma Group International (AAPG). have?

Ascentage Pharma Group International (AAPG) has 0 emplpoyees as of January 15 2026.

What is Ascentage Pharma Group International (AAPG) market cap?

Today AAPG has the market capitalization of 0.00 USD.

AAPG Overview

AAPG Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

People Also Watch

Frequently Asked Questions

What is Ascentage Pharma Group International (AAPG) stock price today?

What is Ascentage Pharma Group International (AAPG)'s business?

What is the price predicton of AAPG Stock?

What is Ascentage Pharma Group International (AAPG)'s revenue for the last quarter?

What is Ascentage Pharma Group International (AAPG)'s earnings per share (EPS) for the last quarter?

How many employees does Ascentage Pharma Group International (AAPG). have?

What is Ascentage Pharma Group International (AAPG) market cap?